Karyopharm Therapeutics (KPTI) Amortization of Deferred Charges (2019 - 2025)

Karyopharm Therapeutics has reported Amortization of Deferred Charges for 7 years, with the latest figure at $2.4 million in Q4 2025.

• For the quarter ending Q4 2025, Amortization of Deferred Charges rose 3.73% year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2025 stood at $10.5 million (up 65.58% YoY), and the FY2025 full-year result was $10.5 million, up 65.58% from the prior year.
• Amortization of Deferred Charges for Q4 2025 stood at $2.4 million, down from $2.8 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $2.8 million in Q3 2025, with the low at $191000.0 in Q1 2021.
• Historically, Amortization of Deferred Charges has averaged $966050.0 across 5 years, with a median of $206500.0 in 2023.
• Annual changes were most pronounced in 2021 — Amortization of Deferred Charges tumbled 90.64% — and 2025, when it surged 1137.02%.
• Karyopharm Therapeutics' Amortization of Deferred Charges stood at $199000.0 in 2021, then advanced by 5.53% to $210000.0 in 2022, then advanced by 3.33% to $217000.0 in 2023, then surged by 986.18% to $2.4 million in 2024, then gained by 3.73% to $2.4 million in 2025.
• The last three Amortization of Deferred Charges figures came in at $2.4 million (Q4 2025), $2.8 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.